Latest Period
Q4 2025
Security Snapshot
vTv Therapeutics Inc. - Class A Common Stock, par value $0.01 per share (VTVT) Institutional Ownership
CUSIP: 918385204
13F Institutional Holders and Ownership History from Q3 2023 to Q1 2026
Institutions Reporting
26
Shares (Excl. Options)
1,283,621
Price
$39.99
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Class A Common Stock, par value $0.01 per share
- Symbol
- VTVT on Nasdaq
- Underlying class
- Class A Common Stock ("Common Stock")
- Shares outstanding
- 3,948,649
- Price per share
- $39.66
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 1,283,621
- Total reported value
- $51,331,630
- % of total 13F portfolios
- 0%
- Share change
- +64,343
- Value change
- +$2,953,481
- Number of holders
- 26
- Price from insider filings
- $39.66
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- VTVT - vTv Therapeutics Inc. - Class A Common Stock, par value $0.01 per share is tracked under CUSIP 918385204.
- 26 institutions reported positions in Q4 2025.
- 4 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 26 to 4 between Q4 2025 and Q1 2026.
- Reported value moved from $51,331,630 to $15,317.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 26 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 918385204?
CUSIP 918385204 identifies VTVT - vTv Therapeutics Inc. - Class A Common Stock, par value $0.01 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 918385204:
Significant Owners of vTv Therapeutics Inc. - Class A Common Stock, par value $0.01 per share (VTVT) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Samsara BioCapital, L.P. | 9.9% | 0% | $12,001,117 | +$1,803,961 | 403,942 | +18% | Srinivas Akkaraju | 08 Dec 2025 |
| Invus Global Management, LLC | 9.4% | -5.9% | $9,179,310 | +$1,051,154 | 393,098 | +13% | Raymond Debbane | 30 Sep 2025 |
| Trails Edge Capital Partners, LP | 9.9% | $5,108,040 | 340,536 | Trails Edge Capital Partners, LP | 29 Aug 2025 | |||
| MILLENNIUM MANAGEMENT LLC | 5.7% | +14% | $8,927,903 | +$1,064,496 | 225,073 | +14% | Millennium Management LLC | 13 Apr 2026 |
As of 31 Dec 2025, 26 institutional investors reported holding 1,283,621 shares of vTv Therapeutics Inc. - Class A Common Stock, par value $0.01 per share (VTVT). This represents 33% of the company’s total 3,948,649 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of vTv Therapeutics Inc. - Class A Common Stock, par value $0.01 per share (VTVT) together control 33% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| SAMSARA BIOCAPITAL, LLC | 7.6% | 298,496 | -20% | 1.2% | $11,936,855 |
| FMR LLC | 6.8% | 268,856 | +39% | 0% | $10,751,551 |
| Trails Edge Capital Partners, LP | 5.9% | 231,000 | 0% | 2.3% | $9,237,690 |
| Siren, L.L.C. | 4.1% | 163,000 | 0% | 0.19% | $6,518,370 |
| BAKER BROS. ADVISORS LP | 3.8% | 148,314 | 0% | 0.03% | $5,931,077 |
| VANGUARD GROUP INC | 2.1% | 83,400 | +77% | 0% | $3,335,166 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.71% | 28,194 | +84% | 0% | $1,127,567 |
| 683 Capital Management, LLC | 0.46% | 18,268 | 0.06% | $730,537 | |
| NORTHERN TRUST CORP | 0.41% | 16,052 | +14% | 0% | $641,919 |
| BlackRock, Inc. | 0.27% | 10,606 | +115% | 0% | $424,134 |
| Pathstone Holdings, LLC | 0.15% | 6,073 | 0% | $242,876 | |
| GOLDMAN SACHS GROUP INC | 0.14% | 5,531 | 0% | $221,185 | |
| UBS Group AG | 0.04% | 1,668 | -44% | 0% | $66,703 |
| Tower Research Capital LLC (TRC) | 0.03% | 1,268 | 0% | $50,707 | |
| OSAIC HOLDINGS, INC. | 0.03% | 1,120 | -31% | 0% | $44,787 |
| MORGAN STANLEY | 0.02% | 977 | +31% | 0% | $39,071 |
| Farther Finance Advisors, LLC | 0.01% | 279 | 0% | $11,157 | |
| CITIGROUP INC | 0.01% | 244 | +24300% | 0% | $9,758 |
| BESSEMER GROUP INC | 0% | 112 | 0% | $4,000 | |
| Activest Wealth Management | 0% | 50 | 0% | 0% | $2,000 |
| CoreCap Advisors, LLC | 0% | 45 | 0% | 0% | $1,800 |
| Parallel Advisors, LLC | 0% | 38 | 0% | 0% | $1,520 |
| Sunbelt Securities, Inc. | 0% | 15 | 0% | 0% | $600 |
| BNP PARIBAS FINANCIAL MARKETS | 0% | 9 | 0% | 0% | $360 |
| BANK OF AMERICA CORP /DE/ | 0% | 4 | +300% | 0% | $160 |
Institutional Holders of vTv Therapeutics Inc. - Class A Common Stock, par value $0.01 per share (VTVT) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 380 | $15,317 | +$162 | $39.66 | 4 |
| 2025 Q4 | 1,283,621 | $51,331,630 | +$2,953,481 | $39.99 | 26 |
| 2025 Q3 | 988,279 | $23,052,921 | +$9,364,357 | $23.35 | 23 |
| 2025 Q2 | 587,143 | $8,742,344 | +$226,154 | $15.00 | 21 |
| 2025 Q1 | 571,712 | $9,902,095 | +$353,201 | $17.32 | 20 |
| 2024 Q4 | 551,416 | $7,570,090 | +$133,643 | $13.81 | 17 |
| 2024 Q3 | 542,324 | $7,337,088 | +$2,516,893 | $13.56 | 20 |
| 2024 Q2 | 348,140 | $6,148,038 | +$252,272 | $17.66 | 19 |
| 2024 Q1 | 333,650 | $7,850,341 | +$6,240,904 | $23.53 | 19 |
| 2023 Q4 | 68,620 | $788,715 | +$781,835 | $11.50 | 14 |
| 2023 Q3 | 600 | $287 | +$287 | $0.48 | 1 |